AC Immune SA
ACIU2.175USD
+0.055+2.59%
交易中 （美东）报价延迟15分钟
218.39M总市值
亏损市盈率 TTM
关于 AC Immune SA 公司
AC Immune SA 是一家位于瑞士的临床阶段生物制药公司。该公司专注于神经退行性疾病的精准医疗。它设计、发现和开发用于预防、诊断和治疗由错误折叠蛋白质引起的疾病的治疗和诊断产品。其 SupraAntigen 和 Morphomer 技术平台可创建抗体、小分子和疫苗，旨在治疗广泛的神经退行性疾病，例如阿尔茨海默病 (AD)。该公司的产品线包括九种治疗产品候选药物（其中五种处于临床试验阶段）和三种诊断候选药物。其主要产品候选药物是 Crenezumab，一种用于治疗阿尔茨海默病的人源化单克隆抗 Abeta 抗体。该公司与罗氏/基因泰克、礼来、百健、杨森制药、雀巢健康科学研究所、生命分子成像（前身为 Piramal Imaging）和 Essex Bio-Technology 等制药公司都有合作。
公司简介
公司代码ACIU
公司名称AC Immune SA
上市日期Sep 23, 2016
CEOProf. Dr. Andrea Pfeifer, Ph.D.
员工数量133
证券类型Ordinary Share
年结日Sep 23
公司地址EPFL Innovation Park
城市LAUSANNE
上市交易所NASDAQ Global Market Consolidated
国家Switzerland
邮编1015
电话41213459121
网址https://www.acimmune.com/
公司代码ACIU
上市日期Sep 23, 2016
CEOProf. Dr. Andrea Pfeifer, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Werner Lanthaler, Ph.D.
Dr. Werner Lanthaler, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
140.00K
+13.65%
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
58.01K
+49.01%
Mr. Piergiorgio Donati
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Chief Technical Operations Officer
45.80K
+86.78%
Mr. Howard Donovan
Mr. Howard Donovan
Chief Human Resources Officer
Chief Human Resources Officer
40.80K
+102.61%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
38.05K
+201.94%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
25.97K
+183.81%
Dr. Anke Post, M.D., Ph.D.
Dr. Anke Post, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.80K
--
Dr. Monica Shaw, M.D.
Dr. Monica Shaw, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Roy E. Twyman, M.D.
Dr. Roy E. Twyman, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Dr. Monika Buetler, Ph.D.
Prof. Dr. Monika Buetler, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Werner Lanthaler, Ph.D.
Dr. Werner Lanthaler, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
140.00K
+13.65%
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
58.01K
+49.01%
Mr. Piergiorgio Donati
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Chief Technical Operations Officer
45.80K
+86.78%
Mr. Howard Donovan
Mr. Howard Donovan
Chief Human Resources Officer
Chief Human Resources Officer
40.80K
+102.61%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
38.05K
+201.94%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
25.97K
+183.81%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月22日 周二
更新时间: 7月22日 周二
持股股东
股东类型
持股股东
持股股东
占比
BVF Partners L.P.
19.74%
DH Capital GmbH & Co. KG
16.25%
Varuma AG
11.95%
Affiris AG
6.40%
Pfeifer (Andrea M. A Ph.D.)
2.94%
Other
42.71%
持股股东
持股股东
占比
BVF Partners L.P.
19.74%
DH Capital GmbH & Co. KG
16.25%
Varuma AG
11.95%
Affiris AG
6.40%
Pfeifer (Andrea M. A Ph.D.)
2.94%
Other
42.71%
股东类型
持股股东
占比
Corporation
34.60%
Hedge Fund
21.05%
Individual Investor
3.40%
Investment Advisor/Hedge Fund
2.09%
Investment Advisor
1.20%
Research Firm
1.02%
Bank and Trust
0.03%
Other
36.62%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
116
63.65M
63.39%
-3.52M
2025Q1
122
64.71M
64.45%
-3.00M
2024Q4
118
65.41M
66.11%
-3.57M
2024Q3
115
69.90M
70.65%
+1.39M
2024Q2
111
70.29M
70.97%
+1.59M
2024Q1
107
70.85M
71.52%
-2.28M
2023Q4
109
71.51M
72.19%
+11.62M
2023Q3
121
61.07M
72.18%
-889.36K
2023Q2
131
61.41M
72.77%
+1.91M
2023Q1
140
59.93M
71.03%
-2.26M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BVF Partners L.P.
19.82M
19.74%
+300.00K
+1.54%
Mar 31, 2025
DH Capital GmbH & Co. KG
16.32M
16.25%
--
--
Dec 31, 2024
Varuma AG
12.00M
11.95%
--
--
Dec 31, 2024
Affiris AG
6.43M
6.4%
-150.00K
-2.28%
May 31, 2024
Pfeifer (Andrea M. A Ph.D.)
2.96M
2.94%
+534.84K
+22.09%
Dec 31, 2024
Wells Fargo Advisors
997.62K
0.99%
+1.99K
+0.20%
Mar 31, 2025
Renaissance Technologies LLC
803.47K
0.8%
+63.27K
+8.55%
Mar 31, 2025
BlackRock Financial Management, Inc.
642.79K
0.64%
-920.44K
-58.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
393.51K
0.39%
-31.72K
-7.46%
Mar 31, 2025
Northern Trust Global Investments Limited
377.09K
0.38%
-25.95K
-6.44%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Health Innovation Active ETF
0%
ALPS Medical Breakthroughs ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
Invesco Nasdaq Biotechnology ETF
占比0.02%
iShares Biotechnology ETF
占比0.01%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
iShares Health Innovation Active ETF
占比0%
ALPS Medical Breakthroughs ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
